At week 52, median percentage changes from baseline in periostin in asthma and CRSwNP patients were −18.93% and −41.08% for dupilumab groups, versus −6.94% and −3.52% for placebo groups (both p < .0001 versus placebo). The gene discussed is POSTN; the disease is asthma.